Gallbladder disease, including cholelithiasis and cholecystitis, occurs more frequently with rapid weight loss
doi:10.1186/s41702-019-0043-1
For new or worsening nephropathy, subcutaneous semaglutide did not significantly reduce the risk (RR 0.83, 95% CI 0.61 to 1.12), but it had a borderline significance compared with placebo (RR 0.81, 95% CI 0.66 to 1.00)
Bu nedenle GLP-1 srecinde ama yalnzca kilo kaybetmek deil, ilacn salad itah kontrol dnemini salkl beslenme, hareket ve davran deiiklii iin bir frsata dntrmek olmaldr
"While GLP-1 medications offer significant benefits for many patients managing diabetes and obesity, it's vital that we as clinicians transparently discuss the potential for gallbladder complications," says Dr